ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

A phase III randomized trial published in the New England Journal of Medicine found that two years of lenalidomide maintenance therapy provides equivalent overall survival to indefinite treatment for standard-risk multiple myeloma patients. The study of 516 patients showed 68.6% vs 69.0% survival rates at seven years, with indefinite treatment associated with higher toxicity and second primary cancer incidence. Results suggest fixed-duration maintenance could become the new standard of care.

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

Chip stocks led a Monday rally, with the Nasdaq Composite gaining 1.3% and the S&P 500 rising 0.7%, while the Dow Jones remained flat. Broadcom surged 4.4% after extending its Apple chip supply deal through 2031, and AMD jumped 8% on autonomous driving adoption. However, Microsoft fell 1.4% following announcements of 4,800 job cuts, and the Dow was weighed down by declines in Honeywell and Amgen.

Alphabet joined the Dow Jones Industrial Average on June 29, replacing Verizon. While Alphabet is a strong company with growing cloud and AI segments, its low dividend yield (0.3%) makes it less suitable for income investors. The article recommends three alternative Dow dividend stocks: Cisco Systems, Coca-Cola, and Amgen, all offering stronger dividend yields and solid year-to-date performance.

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and strong profitability, against Iovance Biotherapeutics, an emerging biotech firm with innovative cancer therapies showing 60.6% revenue growth but still unprofitable. The author recommends Amgen for 2026 due to its stability, dividend, and proven track record, while acknowledging Iovance's compelling science but noting its execution risks and negative cash flow.

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

Amgen has formally requested an FDA hearing to challenge the proposed withdrawal of Tavneos (avacopan), a drug for treating ANCA-associated vasculitis. The company argues that the drug's benefits continue to outweigh its risks and plans to submit detailed data by June 29, 2026. An independent review of the pivotal clinical trial data by Duke Clinical Research Institute is currently underway.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.